


Acid-PEG2-C2-Boc

Cat. No.:	HY-140480
CAS No.:	2086688-99-3
Molecular Formula:	C ₁₂ H ₂₂ O ₆
Molecular Weight:	262.3
Target:	PROTAC Linkers
Pathway:	PROTAC
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (381.24 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	3.8124 mL	19.0621 mL	38.1243 mL
		5 mM	0.7625 mL	3.8124 mL	7.6249 mL
	10 mM	0.3812 mL	1.9062 mL	3.8124 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.53 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.53 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.53 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Acid-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs ^[1] .	
IC ₅₀ & Target	PEGs	Alkyl/ether
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA